1-2 of 2
Hani Gabra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Sonja Loges, Grerk Sutamtewagul, Michael Heuser, Jörg Chromik, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Giovanni Mattei, Isabel Ben Batalla, Monica Hellesøy, Jonas Waizenegger, Melanie Janning, Charles D. Imbusch, Niklas Beumer, Austin Rayford, Jaya Nautiyal, Tzivia Berkman-Gottlieb, David Micklem, Hani Gabra, Claudia Gorcea-Carson, James B. Lorens, Walter Fiedler, Yesid Alvarado, Bjorn T. Gjertsen, Lisa-Marie Rieckmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2021-147225
Published: 2021
Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Sonja Loges, MD PhD, Michael Heuser, Jörg Chromik, MD, Carlos Enrique Vigil, MD, Peter Paschka, MD, Francesca Re, MD, Nicola Di Renzo, MD, Roberto M. Lemoli, Daniele Giovanni Mattei, MD, Isabel Ben-Batalla, PhD, Monica Hellesoy, PhD, Katherine Lorens, MD, Joseph Birkett, PhD, Stuart McPherson, BSc, Jaya Nautiyal, PhD, David Micklem, PhD, Hani Gabra, MD PhD FRCPE, FRCP, James B. Lorens, PhD, Walter Fiedler, MD, Yesid Alvarado, MD, Bjorn T. Gjertsen, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14.
https://doi.org/10.1182/blood-2020-136566
Published: 2020